Mark Edward Moss

US Patent:

7256050, Aug 14, 2007

Filed:

Jun 18, 2001

Appl. No.:

09/882376

Inventors:

John Peter Morseman - Columbia MD, US
Mark Wesley Moss - Baltimore MD, US
F. C. Thomas Allnutt - Port Deposit MD, US

Assignee:

Martek Biosciences Corp. - Columbia MD

International Classification:

G01N 21/76

US Classification:

436172, 436164, 436546, 435 792

Abstract:

In a method for quantitating an analyte by measuring time resolved transfer of fluorescence energy to or from a label quantitatively associated with the analyte, the present invention provides an improvement comprising measuring the energy transferred from donor compounds having the ability to absorb light energy and then transfer this energy to cross-linked allophycocyanin in a time-resolved manner, where the cross-linked allophycocyanin used according to this invention has not been exposed to strongly chaotropic agents after cross-linking.

US Patent:

20090215896, Aug 27, 2009

Filed:

Jan 19, 2005

Appl. No.:

10/597304

Inventors:

John P. Morseman - Columbia MD, US
Mark W. Moss - Baltimore MD, US
Lorie A. Ellis - BelAir MD, US

Assignee:

MARTEK BIOSCIENCES CORPORATION - Columbia MD

International Classification:

A61K 31/201
G01N 33/543
C40B 30/04
C12Q 1/02
C12Q 1/68
C07K 14/47

US Classification:

514560, 436518, 506 9, 435 29, 435 6, 530350

Abstract:

A method of measuring Reelin as a biomarker, to non-destructively assess or predict DHA levels in the brain and in other, currently inaccessible or difficult-to-access, key components of the central nervous system (CNS) is described. Also described is a method to prevent, delay the onset of, or treat Reelin deficiency or dysfunction and/or a disease or condition associated with Reelin deficiency or dysfunction, comprising administering to a patient diagnosed with or suspected of having a Reelin deficiency or dysfunction an amount of a PUFA, and particularly an omega-3 PUFA, and more particularly, docosahexaenoic acid (DHA) or a precursor or source thereof, to compensate for the effects of Reelin deficiency or dysfunction in the patient. Also described is a method to prevent or reduce developmental defects or disorders associated with Reelin dysfunction or deficiency through the supplemental use of polyunsaturated fatty acids (PUFAs—unsaturated fatty acids having two or more double bonds), and particularly highly unsaturated fatty acids (HUFAs—unsaturated fatty acids having three or more double bonds), and more particularly a HUFA selected from arachidonic acid (ARA), eicosapentacnoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA), and even more particularly omega-3 HUFAs, and more particularly DHA, to: compensate for reduced fatty acid binding protein or function thereof in the patient; compensate for reduced brain lipid binding protein or function thereof in the patient; improve the activity of fatty acid binding proteins in the patient; increase the expression of brain lipid binding proteins (BLBPs) in the patient; improve at least one parameter of the mechanism of action of brain lipid binding proteins in the patient; overcome a deficiency of DHA in central nervous system (CNS) structures and improve the resulting function thereof; increase the incorporation of functional DHA and other PUFAs into the phospholipid membranes of glial cells and neurons in the patient; increase the level of Reelin and/or improve the activity of Reelin in the patient; and/or improve at least one symptom of a disease or condition associated with Reelin deficiency or dysfunction.